Y-mAbs Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Y-mAbs Therapeutics (NASDAQ:YMAB) Full Year 2024 Results

Key Financial Results

• Revenue: US$87.7m (up 3.4% from FY 2023).
• Net loss: US$29.7m (loss widened by 39% from FY 2023).
• US$0.67 loss per share (further deteriorated from US$0.49 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Y-mAbs Therapeutics EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.1%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 11% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Y-mAbs Therapeutics you should be aware of, and 1 of them is a bit concerning.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.